As Chemistry World columnist Derek Lowe noted on his blog, such a refusal-to-file is relatively rare, but the message it sends to companies developing new therapies – particularly vaccines – is that the agency is no longer playing by its own rules. Moderna had apparently consulted the FDA on designs ...
